3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
6
Diarrhea
4
Rectal Neoplasms
2
Ovarian Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Short Bowel Syndrome
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Low Anterior Resection Syndrome
1
Exanthema
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Cancer Metastatic
1
Colitis, Ulcerative
1
Colitis
1
Chemotherapy-related Diarrhea
1
Interventions
Fulvestrant
2
ruxolitinib
1
dexpanthenol
1
ceterizine hydrochloride
1
capivasertib
1
benralizumab
1
Triamcinolone Acetonide
1
Tetracycline
1
Provitamins
1
Prednisone
1
Minocycline
1
Loperamide
1
Interviews as Topic
1
Hydrocortisone
1
HIV Testing
1
Gels
1
Fibroblast Growth Factor 7
1
Erlotinib Hydrochloride
1
Doxycycline
1
Dapsone
1
Clindamycin
1
Cetuximab
1
Anti-Bacterial Agents
1
Alpelisib
1
Acitretin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Exanthema
×
Loperamide
×
Clear all
NCT07426822
2026-02-24
SAFE-CAP
Yale University
Phase 2
Not yet recruiting
108 enrolled